Eisai: KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carci

Press/Media

Period14 Sep 2024

Media coverage

1

Media coverage

  • TitleEisai: KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carci
    Media name/outletContify Life Science News
    Country/TerritoryIndia
    Date14/09/24
    PersonsJosep Llovet
View all 1
View less